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Abstract Multidrug resistance (MDR) remains a substantial
problem in chemotherapy. The purpose of the study was to
investigate potential factors, including MDR genes polymor-
phisms, that could be used in qualification for second-line
docetaxel therapy in non-small cell lung cancer (NSCLC) pa-
tients after failure of platinum based chemotherapy. Study
group comprised of 58 Caucasian subjects. Evaluation of
Single Nucleotide Polymorphisms (SNPs) of ABCC2/MRP2
and ABCB1/MDR1 genes was performed using the High
Resolution Melting (HRM) technique. TUBB3 gene expres-
sion was evaluated on RNA isolated from tumor tissue.
Results with p value of <0.05 were considered significant.
Factors associated with reduced risk of disease progression
included good performance status (PS), long period between
diagnosis and docetaxel treatment, and smoking for <10 pack-
years. Disease control occurred more often in patients with
G/G genotype of the ABCC2/MRP2 gene. Median overall
survival was 4.25 months. Factors such as: good PS, disease
control after docetaxel, long period from diagnosis to doce-
taxel, lack of significant weight loss, and third-line treatment
were associated with prolongation of patients survival.
Overall survival probability was significantly lower in patients
with significant weight loss, poor PS, lack of disease control
after docetaxel, and without third-line treatment. Factors that
characterized the highest risk of survival shortening were:
inability to apply third-line treatment, lack of best response
to first-line therapy, poor PS, and C/G or G/G genotypes of
ABCC2/MRP2 gene. We concluded that assessed factors had
mainly prognostic and not predictive value. Finding reliable
molecular predictors for second line docetaxel therapy re-
quires further clinical trials.
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Introduction
Non-small cell lung cancer (NSCLC) accounts for 80% of lung
neoplasms. Early stage of the disease is an indication for sur-
gery, while locally advanced or metastatic NSCLC is treated
with chemotherapy, radiotherapy andmolecularly targeted ther-
apies. Response to first-line therapy is observed in 30–40% of
patients, second line of treatment is even less effective.
Docetaxel is a well-known antimitotic drug that can be
used in second-line treatment after failure of prior platinum
based chemotherapy. It reversibly binds to microtubules (β-
tubulins), stabilizes them and prevents their depolymerization.
It also leads to phosphorylation of BCL-2, which is an
apoptosis-blocking oncoprotein. Therefore, it works by inter-
fering with cell division and inducing cell apoptosis.
Docetaxel is effective in about 10% of patients.
The multidrug resistance (MDR) remains a substantial
problem in development of resistance to chemotherapeutic
treatment. The overexpression of ATP-binding cassette
(ABC) transporters is responsible for cell removal of several
classes of chemotherapeutics including taxanes, vinca
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alkaloids and nucleoside analogs, as well as physiologic sub-
strates including leukotrienes and glutathione. The C subfam-
ily of ABC proteins is alternatively known as the ABCC pro-
teins or the multidrug resistance protein (MRP) subfamily. P-
glycoprotein, a pivotal member of ABC transporters, is the
product of multidrug resistance gene (ABCB1/MDR1).
Polymorphisms (including single nucleotide polymorphisms,
SNPs) ofMDR genes are responsible for differences in expres-
sion and activity of several proteins involved in the removal of
cytostatics form tumor cells.
The purpose of this study was to investigate potential clin-
ical and molecular factors, including MDR genes polymor-
phisms, that could be used in qualification for second-line
docetaxel therapy in patients with NSCLC after failure of
first-line therapy.
Material and Methods
The study group comprised of 58 Caucasian patients with lo-
cally advanced or metastatic NSCLC after failure of first-line
chemotherapy. The staging of disease was determined accord-
ing to the TNM classification (VII edition), and response to
treatment was evaluated according to RECIST version 1.1.
Performance status of patients was assessed in ECOG-WHO
scale. All patients received first-line treatment with platinum-
based chemotherapy. In all patients docetaxel at a dose of
75 mg/m2 was used as a second line treatment. Detailed char-
acteristics of the patients are presented in Table 1.
TUBB3 gene expressionwas evaluated onRNA isolated from
formalin fixed paraffin embedded tumor tissue. Isolation of RNA
was carried out using the RNeasy FFPE Kit (Qiagen, Canada).
SNPs of ABCC2/MRP2 (rs12762549, g.99861014C > G) and
ABCB1/MDR1 (rs1045642, c.3435 T > C) genes were studied
on DNA isolated from peripheral blood leucocytes, using the
QIAmp Blood Mini Kit (Qiagen, Canada). Evaluation of the
quality and quantity of extracted DNA/RNA was carried out
using the BioPhotometer plus (Eppendorf, Germany).
TUBB3 gene expression was assessed using Real-Time
Quantitative Reverse Transcription PCR. Reverse transcrip-
tion reaction was carried out using High Capacity cDNA
Reverse Transcription Kit (Life Technologies, USA) with spe-
cific primers and reverse transcriptase. Expression of mRNA
for TUBB3 gene was analyzed on ABI PRISM 7500 equip-
ment (Life Technologies, USA) using TaqMan Gene
Expression Assay (Life Technologies, USA).
The evaluation of SNPs of ABCC2/MRP2 and ABCB1/
MDR1 genes was performed using the PCR HRM (High
Resolution Melting) technique. Reaction parameters for PCR
and HRMwere based on the manufacturer’s instructions from
the KAPA FAST HRM PCR set (Kapa Biosystems, USA).
PCR HRM was carried out on Eco Illumina (Illumina, USA)
real-time PCR equipment.
Statistical analysis of data was performed using the
MedCalc 10 (MedCalc Software, Belgium) and Statistica 10
(Statsoft, USA) software. Hardy-Weinberg equilibrium and
the impact of demographic, clinical and genetic factors on
the response to treatment and 6-month survival of the patients
was estimated with the use of the Chi Square (χ2) test. Cox
regression model with a stepwise selection of clinical and
molecular factors with the minimum AIC was used to deter-
mine the model having the greatest impact on overall survival.
Kaplan-Meier estimation method was used to compare the
probability of overall survival in patients with different clini-
cal, demographic and genetic characteristics. Large cell carci-
noma and NOS (not-otherwise specified) NSCLC were ex-
cluded from statistical analysis due to its confusing nature
and small number of cases. Also smoking status was excluded
due to the fact, that. Most of patients (94.8%) were classified
as heavy smokers. In all the performed test, results with p
value of <0.05 were considered as statistically significant.
Results
In the distribution of genotypes of the ABCC2 and MDR1
genes there were no deviations from the Hardy-Weinberg
equilibrium. CC genotype of ABCC2 gene was present in
21.1%, CG in 38.5% and GG in 40.4% of patients. In the case
of the MDR1 gene, genotypes CC, CT and TT were found in
15.4%, 44.2% and 40.4% of subjects. The distribution of ge-
notypes of ABCB1/MDR1 and ABCC2/MRP2 genes did not
depended on demographic and clinical factors.
The median value of ΔCt for TUBB3 gene (relative to the
reference gene ACTB – β-actin) was 5.9 cycles (± 5.41 cycles).
Low expression ofmRNA (belowmedian value ofΔCt) for the
TUBB3 gene have been reported in 54.6%, while high expres-
sion in 45.4% of patients. Expression of mRNA for the TUBB3
gene didn’t depended on demographic or clinical factors.
Among the studied patients, there were no complete remis-
sions. Disease control was achieved in 14 patients (24.1%), 44
patients (75.9%) experienced early progression. Partial remis-
sion was observed in 4 patients (6.9%) In patients who
reached disease control, median time to progression after do-
cetaxel was 5 months (± 10.5 months).
Factors associated with reduced risk of early progression
included: good PS (HR = 0.57, 95%CI: 0.38–0.85,
p = 0.0019), long (>12 months) period between diagnosis of
NSCLC and docetaxel treatment (HR = 0.69, 95%CI: 0.47–
0.99, p = 0.0437). Disease control occurred significantly more
often (HR = 0.71, 95%CI: 0.52–0.98, p = 0.0323) in patients
with GG genotype of the ABCC2/MRP2 gene than in carriers
of other genotypes. For the remaining analyzed genes there
was no significant difference in the incidence of progression
or disease control depending on the presence of studied SNPs.
Similarly, there was no significant difference in response to
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Table 1 Characteristics of patients and influence of clinical factors on response to second-line docetaxel therapy in NSCLC patients
Factors Cases Response to treatment Overall survival






















































































































































































































*not included in the statistical analysis
a including 13 patients treated with erlotinib without molecular selection
b not included in the survival analysis (subgroup of patients, who underwent surgical treatment was not large enough)
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treatment depending on the level of expression of the TUBB3
gene. Relationships between clinical and molecular factors
and occurrence of early progression are presented in Table 2.
The median overall survival was 4.25 months (±
9.6 months). In 24 patients (41.4%) survival was longer than
6 months. Factors such as: good PS (HR = 0.26, 95%CI: 0.12–
0.58, p < 0.0001), disease control after docetaxel (HR = 0.091,
95%CI: 0.014–0.63, p < 0.0001), long period from diagnosis to
docetaxel (HR = 0.35, 95%CI: 0.17–0.71, p = 0.0004), lack of
significant weight loss prior to treatment (HR = 0.48, 95%CI:
0.32–0.73, p = 0.0021) and the use of third-line treatment
(HR = 0.48, 95%CI: 0.24–0.94, p = 0.0195) were asso-
ciated with prolongation of survival beyond 6 months.
Other clinical factors did not have a significant effect
on the 6 months survival. We found no significant impact of
individual SNPs or TUBB3 gene expression on the survival
longer than 6 months.
Overall survival probability estimated by the Kaplan-Meier
method was lower in patients with significant weight loss
(HR = 3.51, 95CI%: 1.61–7.62; p = 0.0015), poor PS
(HR = 3.47, 95CI%: 1.89–6.37; p < 0.0001), lack of disease
control after docetaxel (HR = 2.89, 95CI%: 1.60–5.21;
p = 0.0004), and unable to receive third-line treatment
(HR = 2.25, 95CI%: 1.26–4.01; p = 0.0059). There was no
significant impact of individual SNPs as well as TUBB3 gene
expression on overall survival probability.
Although it seems that the applied treatment has a higher
efficacy in the SCC subgroup of patients, we have failed to
demonstrate a statistically significant effect on overall survival
(Table 3). Kaplan-Meier survival curves of NSCLC and SCC
patients with different ABCC2/MRP1 genotypes were shown
in Figs. 1 and 2.
According to the Cox model (general model fit:
p = 0.0024) demographic, clinical and genetic factors that
characterized the highest risk of survival shortening were: lack
of third-line treatment (HR = 23.89, 95%CI: 3.50–163.02,
p = 0.0013), lack of best response to first-line therapy
(HR = 11.34, 95%CI: 2.04–63.11, p = 0.0058), poor PS
(HR = 7.06, 95%CI: 1.59–31.32, p = 0.0105), and CG or
GG genotypes of ABCC2/MRP2 gene (HR = 5.21, 95%CI:
1.08–25.05, p = 0.0404).
Discussion
TAX 317 [1] and TAX 320 [2] studies demonstrated effective-
ness of docetaxel after failure of first-line chemotherapy. In the
TAX 317 study, both the median survival (7.5 months) as well
Table 2 Influence of genetic alterations on response to second-line docetaxel therapy in NSCLC patients
Factors Cases Response to treatment Overall survival
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as the 12 month survival rate (37%) were significantly higher
in patients treated with docetaxel compared to patients receiv-
ing best supportive care (4.6 months and 11%, retrospective-
ly). In the TAX 320 study, response occurred in 7.5–11.9% of
patients depending on the dose of docetaxel, and in 1% of
patients in the control group receiving vinorelbine or
ifosfamide. 12month survival rate was 32% in patients treated
with docetaxel and 19% in the control group. Second line
treatment can be used in patients with PS scored at 0–1, and
in exceptional cases with PS = 2. Patients with PS > 2 should
not be treated [3]. The results obtained in our study confirm
that PS is critical, affecting all of the analyzed parameters of
treatment effectiveness: the risk of early progression, overall
survival, and risk of death. The median survival of patients in
good PS (PS ≤ 1) was 8 months, while patients in worse
condition (PS > 1) only survived 3 months.
One of the few studies which address the problem of de-
termining predictors of benefit from second-line treatment in
NSCLC is a phase III study by Hanna et al. [4] comparing the
efficacy of docetaxel and pemetrexed. Analysis showed sig-
nificantly longer survival among women, patients with stage
IIIB, in good PS (PS ≤ 1) and with objective response to first-
line treatment. Unfortunately, the study involved patients who
qualified under strict criteria – 89% of them were in good or
very good PS (PS ≤ 1). Median survival for patients with
PS = 0 was 12.7 months, compared to 8.3 months for patients
with PS = 1 and 2.6 months for PS = 2. Median survival was
9.4 months for women, and 7.2 months for men. Similar dif-
ferences were observed in patients differentiated by stage of
disease (IIIB vs. IV). Patients with objective response to first-
line treatment achieved longer survival than patients with sta-
ble disease (median 15.8 vs 10.5 months), and patients from
both above groups fared better than those who progressed
(median survival of 4.6 months).
In the univariate analysis, Weiss et al. [5] found a longer
median survival in patients with non-squamous NSCLC and
with first-line response >3 months. In authors study PS of
60.3% of patients was rated as 2, which resulted in shorter
median survival. Multivariate analysis showed that in addition
to the factors mentioned in the analysis by Weiss et al., sur-
vival was also affected by substantial weight loss (>5%), male
sex, lack of surgical treatment prior to chemotherapy and
third-line treatment after docetaxel.
Tibaldi et al. [6] treated older patients (70–83 years, median
74 years) with reduced dose (37.5 mg/m2) of docetaxel.
Despite the reduction 21% of patients reached partial remis-
sion, and another 36% stable disease. Those results were bet-
ter than in both TAX studies. This probably isn’t associated
Table 3 Influence of genetic alterations on response to second-line docetaxel therapy in subgroup of SCC patients
Factors Cases Response to treatment Overall survival
SD, PR PD p OR
95%CI
Median OS (months) p HR
(95%CI)
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with greater effectiveness of docetaxel in this age group, but
with slower course of the disease in the elderly.
In a study evaluating the effect of prior first-line treatment on
effectiveness of second-line docetaxel in patients with NSCLC,
Macedo-Pérez et al. [7] showed that long (>6 months) response
to first-line treatment is associated with significant increase in
time to progression (TTP) and overall survival.
Our results confirmed crucial predictive role of such factors
as: poor PS, significant weight loss and short time from diag-
nosis to docetaxel treatment. However, we have found no
effect of gender, age, stage of disease or pathological diagno-
sis on overall survival of NSCLC patients treated with doce-
taxel. Interpretation of impact of the third-line treatment after
docetaxel is difficult. We found that third-line therapy can
significantly increase the probability of survival longer than
6 months. However, such treatment is used in patients with
good PS, which is the most important predictive factor.
In the absence of independent predictors that could help
qualify for second-line docetaxel treatment, currently the big-
gest hope rests on molecular research. It has been shown that
patients with high expression of class III β-tubulin benefit less
from paclitaxel treatment [8]. In meta-analysis of 10 clinical
trials in which NSCLC was treated with paclitaxel and/or
vinorelbine, Zhang et al. [9] demonstrated a correlation be-
tween low expression of mRNA for the TUBB3 gene and
favorable outcomes – in the group of patients with low expres-
sion percentage of objective response was higher, and median
survival longer. Kaira et al. [10] evaluated effects of class III
Fig. 1 Survival curves of
NSCLC patients with different
ABCC2/MRP1 genotypes
Fig. 2 Survival curves of SCC
patients with different ABCC2/
MRP1 genotypes
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β-tubulin expression on progression-free survival and overall
survival in patients with NSCLC treated with taxanes.
Researchers demonstrated that in patients treated with doce-
taxel high TUBB3 expression is predictive for short time to
progression and concluded that it is associated with resistance
to taxanes. In our study no significant difference in response to
therapy, probability of survival longer than 6 months, or over-
all survival was found depending on the level of mRNA ex-
pression of the TUBB3 gene.
In normal lung, ABCB1 is expressed on the surface of
bronchi and at the plasmamembrane of alveolar macrophages.
In lung cancer, ABCB1 expression is initially low, but this
may change after exposure to chemotherapy as part of ac-
quired drug resistance. ABCB1 confers resistance to cytotoxic
drugs, including etoposide and cisplatin. ABCC2 is expressed
at low levels in normal lung tissue and at high levels in lung
cancer. It has higher expression in poorly differentiated com-
pared to well-differentiated tumors. This suggests that these
tumors may quickly develop resistance to anti-cancer agents.
In tumor cell lines, ABCC2 mRNA overexpression was asso-
ciated with resistance to etoposide, vincristine, cisplatin,
doxorubicin and epirubicin.
Haenish S et al. [11] showed that ABCB1MDR1 and
ABCC2/MRP2 SNPs modulate the expression of multidrug
resistance protein in the unaffected renal cortex of renal cell
carcinoma patients. In Meyer et al. [12] study, high MRP2
expression was correlated with ABCC2 gene variants (espe-
cially rs717620) in liver tissue. Such correlation was not found
between ABCB1/MDR1 SNPs and MDR1 expression. Allelic
variants of the ABCC2/MRP2 gene have also been associated
with toxicity induced by chemotherapy agents and lung cancer
survival. Few reports suggest that polymorphisms in ABCB1/
MDR1 significantly influence the therapeutic response in lung
cancer, although these findings are not always concordant.
Therefore, MDR genes polymorphisms possibly contribute
to inter-individual differences in drug and xenobiotics elimi-
nation and chemotherapy efficacy. However, the role ofMDR
genes SNPs in docetaxel susceptibility or resistance needs
further investigation in non-small cell lung cancer patients.
Previous studies related to polymorphisms of MDR genes
and chemotherapy effectiveness were conducted mainly in the
populations of Asian origin. Isla et al. [13] studied the effects
of SNPs of ERCC1, XPD, RRM1, ABCB1/MDR1 genes, and
mRNA expression for ERCC1 on overall survival in patients
with advanced NSCLC treated with docetaxel and cisplatin.
Authors ascertained that evaluation of ERCC1 gene SNPs
may be an important factor for effectiveness of platinum-
based chemotherapy. However, analysis of the MDR1 gene
polymorphisms showed no statistically significant results.
In their 2008 paper, Kiyotani et al. [14] studied the effects
of SNPs in seven genes potentially associated with transport
and metabolism of docetaxel (CYP3A4, CYP3A5, ABCB1/
MDR1, ABCC2/MRP2, SLCO1B3, NR1I2 and NR1I3) in
Japanese patients with NSCLC. Polymorphisms in ABCC2
(rs12762549) and SLCO1B3 (rs11045585) genes were signif-
icantly associated with the risk of docetaxel induced leucope-
nia. In combined evaluation of both polymorphisms, patients
with unfavorable genotype proved to have significantly higher
risk of neutropenia compared to patients with favorable geno-
type. Assessment system based on the genotyping of patients
allowed to correctly classify 69.2% of patients with severe
neutropenia and 75.7% of patients without this adverse effect
to the appropriate categories, confirming that the SNPs in
ABCC2 and SLCO1B3 genes may be a predictive factor for
docetaxel induced neutropenia.
In a paper describing Caucasian patients, Campa et al. [15]
characterized the genetic variability of genes ABCB1/MDR1,
ABCC2 and ABCG2 in lung cancer patients treated with che-
motherapy. Of the studied polymorphisms, SNP rs717620 of
the ABCC2 gene has been linked to differences in treatment
response, progression-free survival and overall survival of pa-
tients with small cell lung cancer (SCLC), but this effect was
not observed in NSCLC. Lewis et al. [16] in their study which
included 64 American NSCLC patients receiving docetaxel
showed that SNP rs12762549 of the ABCC2 gene is associat-
ed with reduced clearance of the docetaxel. In our study, in the
model including demographic, clinical and genetic factors,
SNP rs12762549 of the ABCC2 gene (C/G and G/G geno-
types) was one of the factors that had a significant impact on
the risk of shortened overall survival.
Conclusions
Based on the results of our study it can be concluded that
second-line docetaxel monotherapy in the treatment of
NSCLC has limited efficacy, and qualification of patients for
this type of treatment requires a careful analysis of available
prognostic and predictive factors. Factors assessed in this study
mainly have prognostic and not predictive value, which is con-
sistent with the results of other researchers. Molecular studies,
especially of the genes whose protein products are responsible
for the clearance of cytostatics from tumor cells, may be useful
in the selection of patients for docetaxel monotherapy. Finding
reliable molecular predictors for this type of therapy however
requires randomized, prospective clinical trials.
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